{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T04:59:03Z","timestamp":1769749143394,"version":"3.49.0"},"reference-count":28,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2012,5,1]],"date-time":"2012-05-01T00:00:00Z","timestamp":1335830400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2012,5]]},"DOI":"10.1016\/j.ejca.2012.02.048","type":"journal-article","created":{"date-parts":[[2012,3,19]],"date-time":"2012-03-19T20:54:15Z","timestamp":1332190455000},"page":"1023-1030","source":"Crossref","is-referenced-by-count":46,"title":["Progression free survival of first line vascular endothelial growth factor-targeted therapy is an important prognostic parameter in patients with metastatic renal cell carcinoma"],"prefix":"10.1016","volume":"48","clinical-trial-number":[{"clinical-trial-number":"nct00083889","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00130897","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00410124","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00655252","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00835978","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Christoph","family":"Seidel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonas","family":"Busch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steffen","family":"Weikert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra","family":"Steffens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Fenner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arnold","family":"Ganser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Viktor","family":"Gr\u00fcnwald","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2012.02.048_b0005","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJMoa065044","article-title":"Sunitinib versus interferon alfa in metastatic renal-cell carcinoma","volume":"356","author":"Motzer","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2012.02.048_b0010","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1200\/JCO.2009.23.9764","article-title":"Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial","volume":"28","author":"Sternberg","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2012.02.048_b0015","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa060655","article-title":"Sorafenib in advanced clear-cell renal-cell carcinoma","volume":"356","author":"Escudier","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2012.02.048_b0020","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1016\/S0140-6736(07)61904-7","article-title":"Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised double blind phase III trial","volume":"370","author":"Escudier","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2012.02.048_b0025","doi-asserted-by":"crossref","first-page":"4256","DOI":"10.1002\/cncr.25219","article-title":"Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors","volume":"116","author":"Motzer","year":"2010","journal-title":"Cancer"},{"issue":"9807","key":"10.1016\/j.ejca.2012.02.048_b0030","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1016\/S0140-6736(11)61613-9","article-title":"Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial","volume":"378","author":"Rini","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2012.02.048_b0035","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1200\/JCO.20.1.289","article-title":"Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma","volume":"20","author":"Motzer","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2012.02.048_b0040","doi-asserted-by":"crossref","first-page":"5794","DOI":"10.1200\/JCO.2008.21.4809","article-title":"Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study","volume":"27","author":"Heng","year":"2009","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.ejca.2012.02.048_b0045","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1186\/1471-2407-11-295","article-title":"Intrinsic resistance to tyrosine kinase inhibitors is associated with poor clinical outcome in metastatic renal cell carcinoma","volume":"14","author":"Busch","year":"2011","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ejca.2012.02.048_b0050","article-title":"Progression-free survival as a predictor of overall survival in metastatic renal cell carcinoma treated with contemporary targeted therapy","author":"Heng","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2012.02.048_b0055","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ejca.2012.02.048_b0065","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2011.29.15_suppl.4555","article-title":"The association of clinical outcome to front-line VEGF-targeted therapy with clinical outcome to second-line VEGF-targeted therapy in metastatic renal cell carcinoma (mRCC) patients (Pts.)","volume":"29","author":"Al-Marrawi","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2012.02.048_b0070","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2011.29.7_suppl.lba308","article-title":"Randomized phase II multicenter study of the efficacy and safety of sunitinib on the 4\/2 versus continupus dosing schedule as first-line therapy of metastatic renal cell carcinoma: Renal EFFECT Trial","volume":"29","author":"Motzer","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2012.02.048_b0075","doi-asserted-by":"crossref","first-page":"E250","DOI":"10.1111\/j.1464-410X.2011.10186.x","article-title":"Sequential use of sorafenib and sunitinib in advanced renal-cell carcinoma (RCC): an Italian multicentre retrospective analysis of 189 patient cases","volume":"108","author":"Porta","year":"2011","journal-title":"BJU Int"},{"key":"10.1016\/j.ejca.2012.02.048_b0080","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2011.29.7_suppl.305","article-title":"Primary anti-VEGF-refractory metastatic renal cell carcinoma (mRCC): clinical characteristics, risk factors, and subsequent therapy","volume":"29","author":"Heng","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2012.02.048_b0085","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2011.29.15_suppl.4553","article-title":"Circulating baseline plasma cytokines and angiogenic factors (CAF) as markers of tumor burden and therapeutic response in a phase III study of pazopanib for metastatic renal cell carcinoma (mRCC)","volume":"29","author":"Liu","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2012.02.048_b0090","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1111\/j.1464-410X.2010.09218.x","article-title":"Carbonic anhydrase IX and pathological features as predictors of outcome in patients with metastatic clear-cell renal cell carcinoma receiving vascular endothelial growth factor-targeted therapy","volume":"106","author":"Choueiri","year":"2010","journal-title":"BJU Int"},{"key":"10.1016\/j.ejca.2012.02.048_b0095","doi-asserted-by":"crossref","first-page":"3312","DOI":"10.1200\/JCO.2008.19.5511","article-title":"Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial","volume":"27","author":"Escudier","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2012.02.048_b0100","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1111\/j.1464-410X.2006.06376.x","article-title":"Clinical response to therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: impact of patient characteristics and Von Hippel-Lindau gene status","volume":"98","author":"Rini","year":"2006","journal-title":"BJU Int"},{"key":"10.1016\/j.ejca.2012.02.048_b0105","doi-asserted-by":"crossref","first-page":"3743","DOI":"10.1200\/JCO.2007.15.5416","article-title":"Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma","volume":"26","author":"Rini","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2012.02.048_b0110","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1186\/1471-2407-10-695","article-title":"Circulating endothelial cells are an early predictor in renal cell carcinoma for tumor response to sunitinib","volume":"10","author":"Gruenwald","year":"2010","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ejca.2012.02.048_b0115","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s10456-009-9133-9","article-title":"Increased numbers of small circulating endothelial cells in renal cell cancer patients treated with sunitinib","volume":"12","author":"Vroling","year":"2009","journal-title":"Angiogenesis"},{"issue":"5","key":"10.1016\/j.ejca.2012.02.048_b0120","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/1479-5876-5-32","article-title":"Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins","volume":"1","author":"Deprimo","year":"2007","journal-title":"J Transl Med"},{"key":"10.1016\/j.ejca.2012.02.048_b0125","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1593\/tlo.09277","article-title":"Biomarker development for the clinical activity of the mTOR inhibitor everolimus (RAD001): processes, limitations, and further proposals","volume":"3","author":"O\u2019Reilly","year":"2010","journal-title":"Transl Oncol"},{"key":"10.1016\/j.ejca.2012.02.048_b0130","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1007\/s00280-005-0120-6","volume":"57","author":"Lee","year":"2006","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.ejca.2012.02.048_b0135","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.1158\/1078-0432.CCR-06-0919","article-title":"Blood-based biomarkers of SU11248 activity and clinical outcome in patients with metastatic imatinib-resistant gastrointestinal stromal tumor","volume":"13","author":"Norden-Zfoni","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2012.02.048_b0140","doi-asserted-by":"crossref","first-page":"2766","DOI":"10.1172\/JCI32479","article-title":"Angiogenic factors FGF2 and PDGF-BB synergistically promote murine tumor neovascularization and metastasis","volume":"117","author":"Nissen","year":"2007","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ejca.2012.02.048_b0145","doi-asserted-by":"crossref","unstructured":"Escudier B, Association of single nucleotide polymorphisms (SNPs) in VEGF pathway genes with progression-free survival (PFS) and blood pressure (BP) in metastatic renal cell carcinoma (mRCC) in the phase 3 trial of axitinib versus sorafenib (AXIS trial). ECCO16-ESMO36 congress 2011 [abstr. 7103].","DOI":"10.1016\/S0959-8049(11)72018-4"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804912001852?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804912001852?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,6,25]],"date-time":"2019-06-25T16:38:03Z","timestamp":1561480683000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804912001852"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,5]]},"references-count":28,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2012,5]]}},"alternative-id":["S0959804912001852"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2012.02.048","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2012,5]]}}}